EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?

Elena Fornari, Claudia Stefanutti, Valentina Mancioppi, Gerald F Watts, Livia Pisciotta, Anita Morandi, Claudio Maffeis

Journal of Clinical Lipidology · 2025

DOI: 10.1016/j.jacl.2025.02.012 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Elena Fornari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Diabetes and Metabolism, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, Verona, Italy (Drs …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Homozygous Familial Hypercholesterolemia, Anticholesteremic Agents, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ultragenyx Pharmaceutical Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rare homozygous form of familial hypercholesterolemia (HoFH) is characterized by extremely high low-density lipoprotein (LDL) cholesterol levels, typically exceeding 13 mmol/L (500 mg/dL), and a variable phenotype that may include marked premature atherosclerotic cardiovascular disease. HoFH with null-null LDL receptor mutations can be highly resistant to standard pharmacological therapies. The standard of care treatment option is lipoprotein apheresis (LA). However, LA is not commonly available, is technically demanding, and is relatively invasive and arduous for very young patients. Here we report effective lowering of the LDL cholesterol in a 13-month-old child with HoFH treated with evinacumab, initially at a low dose (7.5 mg/kg), later increased to 15 mg/kg/28 days. The decision was made after the failure of standard drug therapies in a sibling with the same null-null mutation in the LDL receptor, submitted to liver transplantation, who had severe complications. The treatment with evinacumab was safe and effective; LDL cholesterol, triglycerides, and apolipoprotein B concentrations all decreased by over 80%. Our findings suggest that evinacumab is a safe and effective option for treating very young patients with HoFH who do not respond to conventional therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalHomozygous Familial HypercholesterolemiaAnticholesteremic AgentsHyperlipoproteinemia Type IIHumansInfantCholesterol, LDLMaleReceptors, LDLTreatment OutcomeFemale

Stichwörter der Autor:innen

Angiopoietin-like 3 protein inhibitorsChildDyslipidemiaEvinacumabHomozygous familial hypercholesterolemiaLDL cholesterol

Substanzen

evinacumabAntibodies, MonoclonalCholesterol, LDLReceptors, LDLAnticholesteremic Agents

Autor:innen und Institutionen

  • Section of Pediatric Diabetes and Metabolism, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, Verona, Italy (Drs Fornari, Mancioppi, Morandi, Maffeis).
  • Department of Molecular Medicine, Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre for Rare Diseases, Immunohematology and Transfusion Medicine, Umberto I H…
  • Section of Pediatric Diabetes and Metabolism, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, Verona, Italy (Drs Fornari, Mancioppi, Morandi, Maffeis). Electronic address: valentina.m…
  • The School of Medicine, University of Western Australia, Perth, Western Australia, Australia (Dr Watts); Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (Dr Wat…
  • The Department of Internal Medicine, University of Genoa, Genoa, Italy (Dr Pisciotta); The IRCCS Hospital San Martino, Genoa, Italy (Dr Pisciotta).

Förderung

  • Ultragenyx Pharmaceutical Inc

Zitieren

APA

Fornari, E., Stefanutti, C., Mancioppi, V., Watts, G. F., Pisciotta, L., Morandi, A., & Maffeis, C. (2025). Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.02.012

Vancouver

Fornari E, Stefanutti C, Mancioppi V, Watts GF, Pisciotta L, Morandi A, et al. Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.02.012

BibTeX
@article{Fornari2025,
  author = {Fornari, Elena and Stefanutti, Claudia and Mancioppi, Valentina and Watts, Gerald F and Pisciotta, Livia and Morandi, Anita and Maffeis, Claudio},
  title = {Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?},
  journal = {Journal of Clinical Lipidology},
  year = {2025},
  doi = {10.1016/j.jacl.2025.02.012}
}
Kostenlos starten →